An employee checks the production of chloroquine phosphate at a pharmaceutical company in Nantong city in east China's Jiangsu province, Thursday, Feb. 27, 2020. (Getty Images)
March 24, 2020 07:06 AM EDTUpdated 01:02 PM
Coronavirus

'I have a feel­ing': Trump-en­dorsed malar­ia drug fails to pass muster in small Chi­nese coro­n­avirus study

Natalie Grover

Reporter

De­spite the FDA’s re­luc­tance to en­dorse with­out de­fin­i­tive clin­i­cal tri­al da­ta the decades-old an­ti-malar­i­al drugs chloro­quine and de­riv­a­tive hy­drox­y­chloro­quine as treat­ments to com­bat the coro­n­avirus …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times